What is Wall Street's Target Price for CTI BioPharma Corp (CTIC) Stock Monday?

Monday, May 22, 2023 01:03 PM | InvestorsObserver Analysts

Mentioned in this article

What is Wall Street's Target Price for CTI BioPharma Corp (CTIC) Stock Monday?

Analysts who follow CTI BioPharma Corp (CTIC) on average expect it to rise 17.13% over the next twelve months. Those same analysts give the stock an average rating of Buy. That average rating earns CTI BioPharma Corp an Analyst Ranking of 20, which means it ranks higher than 20 of stocks, based on data compiled by InvestorsObserver.

Wall Street analysts are rating CTIC a Buy today. Find out what this means to you and get the rest of the rankings on CTIC!

See Full CTIC Report

Why are Analyst Ratings Important?

You can learn a lot about a company from looking at it’s financial statements and comparing them to other companies. Analysts who cover an industry in depth can add even more to your research though. They typically follow a particular sector or industry very closely. They also pay attention to and ask questions on earnings conference calls and other events where they might learn information that does show up in the numbers. InvestorsObserver takes the average rating from these analysts, and then percentile ranks those averages. This lets you compare stocks in a much more granular way than just seeing the typical five-tiered rating system used on most of Wall Street.

What's Happening With CTI BioPharma Corp Stock Today?

CTI BioPharma Corp (CTIC) stock is flat 0% while the S&P 500 has risen 0.09% as of 1:03 PM on Monday, May 22. CTIC is flat $0.00 from the previous closing price of $8.94 on volume of 1,530,187 shares. Over the past year the S&P 500 is up 5.59% while CTIC has risen 75.29%. CTIC lost -$0.58 per share the over the last 12 months. Click Here to get the full Stock Report for CTI BioPharma Corp stock.